Peptides News and Research

RSS

Stimulating effect of bioactive collagen peptides in cell experiments demonstrated

Working in collaboration with Kiel University, researchers at the Kiel- based Collagen Research Institute (CRI) have demonstrated the stimulating effect of special bioactive collagen peptides (FORTIGEL(R)) in the context of cell experiments. Last weekend the CRI presented its research findings at the congress of the Osteoarthritis Research Society International (OARSI) in Montreal.

15 Sep 2009

GENova to file for Prostaganin patents in the US and in Europe

GENova Biotherapeutics Inc. ("GENova") today announced that it is preparing for patent application filings in both the US (at the FDA (U.S. Food and Drug Administration (www.fda.gov) for a 510(k) submission) and in Europe through EMEA (European Medicines Agency) subsequent to expected efficacious and non-toxic pre-clinical results for Prostaganin.

14 Sep 2009

Amylin and Biocon collaborate to develop a peptide therapeutic for treating diabetes

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Biocon, Limited (NSE: BIOCON) announced today that they have entered into an exclusive agreement to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin and Biocon will collaborate to develop the therapeutic potential of the compound and share development costs. Research will center on Amylin's "phybrid" technology.

11 Sep 2009

Merck update on the status of telcagepant clinical development programs

Merck & Co., Inc. today updated the status of the clinical development programs for telcagepant (MK-0974) and MK-3207, the Company's investigational oral calcitonin gene-related peptide (CGRP) receptor antagonists for the intermittent treatment of acute migraine.

11 Sep 2009

Phase II human clinical trial of Exsulin commences

Exsulin Corporation today announced the start of a phase II human clinical trial of Exsulin, a peptide drug product aimed at restoring insulin production in people with diabetes mellitus. The randomized, controlled 12-week trial in patients with established Type 1 diabetes (T1DM) will be co-led by Mayo Clinic in Rochester, Minn., and McGill University Health Centre in Montreal, Canada.

10 Sep 2009

Esperance Pharmaceuticals begins human clinical trials of its EP-100 cancer therapeutic candidate

Drug discovery and development company Esperance Pharmaceuticals today announced that it has begun enrollment and dosing of patients in a Phase 1 study of EP-100 in patients with advanced solid tumors. EP-100, the lead candidate from Esperance's Cationic Lytic Peptide (CLYP(TM)) platform technology, is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.

10 Sep 2009

UCSB researchers use lasers to deliver drugs into cancer cells

Researchers at UC Santa Barbara have developed a new way to deliver drugs into cancer cells by exposing them briefly to a non-harmful laser. Their results are published in a recent article in ACS Nano, a journal of the American Chemical Society.

10 Sep 2009

ARUP Laboratories' scientist receives grant to research HIV therapies

ARUP Laboratories, a national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, announced that ARUP's Tanya Sandrock, PhD, Research & Development scientist, received a prestigious National Institutes of Health (NIH) grant to research additional HIV therapies.

9 Sep 2009

GENova Biotherapeutics files patent for Prostaganin anti-cancer drug

GENova Biotherapeutics, Inc., ("GENova"), is pleased to announce that it has filed a patent for a novel peptide that disrupts the advance of prostate cancer and thus has blockbuster potential as a new anti-cancer drug.

9 Sep 2009

Iterative in situ click chemistry creates antibody-like protein-capture agents

Chemists at the California Institute of Technology (Caltech) and The Scripps Research Institute (SRI) have developed an innovative technique to create cheap but highly stable chemicals that have the potential to take the place of the antibodies used in many standard medical diagnostic tests. James R. Heath, Ph.D., principal investigator of the Nanosystems Biology Cancer Center at Caltech, one of eight Centers of Cancer Nanotechnology Excellence, and K. Barry Sharpless, Ph.D., SRI, and their colleagues describe the new technique in the journal Angewandte Chemie International Edition.

7 Sep 2009

Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth

When bees sting, they pump into their victims a peptide toxin called melittin that destroys cell membranes. Now, by encapsulating this extremely potent molecule within a nanoparticle, researchers at the Washington University School of Medicine in St. Louis have created a potential new type of anticancer therapy with the potential to target a wide range of tumors. This work was reported in the Journal of Clinical Investigation.

7 Sep 2009

CIHR funds for Alzheimer's and stroke research

The Canadian Institutes of Health Research (CIHR) has announced a grant totaling more than a million dollars for John F. MacDonald's research on Alzheimer's disease.

7 Sep 2009

New protein fragments identified for anthrax vaccine development

Researchers at Albert Einstein College of Medicine of Yeshiva University have identified two small protein fragments that could be developed into an anthrax vaccine that may cause fewer side effects than the current vaccine.

4 Sep 2009

Researchers identify new molecular switch that produces cancer cells

A team of Syracuse University researchers discovered a second molecular switch within the Mixed Lineage Leukemia protein complex that they believe could be exploited to prevent the overproduction of abnormal cells that are found in several types of cancer, including leukemia.

4 Sep 2009

Gloucester’s romidepsin recommended for approval by the FDA Oncologic Drug Advisory Committee

Gloucester Pharmaceuticals announced today that the Oncologic Drug Advisory Committee (ODAC) appointed by the U.S. Food and Drug Administration (FDA) voted 10 in favor with one abstention to recommend approval of romidepsin to treat patients with cutaneous T-cell lymphoma (CTCL). CTCL is a type of non-Hodgkin's lymphoma, which is a cancer of the immune system.

3 Sep 2009

BioMS Medical update on dirucotide development

BioMS Medical Corp. (TSX: MS), today provided an update on developments in respect of dirucotide, its drug candidate for multiple sclerosis (MS).

2 Sep 2009

Hope for limiting skin toxicity of cancer drug users

There may be a way around the harsh skin toxicity associated with a widely used cancer drug, according to a study published online this week in Cancer Biology and Therapy by researchers from City of Hope and the Kimmel Cancer at Jefferson.

2 Sep 2009

Induced antibodies neutralize HIV-1; recognize peptides encapsulated in liposomes

For the first time, researchers have experimentally induced antibodies that neutralize HIV-1 and simultaneously recognize both HIV-1 envelope protein and lipids. The results were reported by U.S. Military HIV Research Program (MHRP) researchers on Aug. 25 in the online version of AIDS, the official journal of the International AIDS Society.

2 Sep 2009

Grant awarded to two researchers to study the role of GLP-1 in people at risk for or with diabetes

The American Diabetes Association Research Foundation has selected two scientists, University of Virginia Health System researcher Zhenqi Liu, MD, and Stanford University School of Medicine researcher Gerald Reaven, MD, to receive the American Diabetes Association-Novo Nordisk Clinical/Translational Research Award. This $1.2 million grant program supports efforts to study the effects of intestinal hormones, such as glucagon-like peptide-1 (GLP-1), on obesity and pre-diabetes, two risk factors for type 2 diabetes and cardiovascular disease.

2 Sep 2009

Paper discussing the mechanism of the selective TGR5 agonist INT-777 published in Cell Metabolism

Bile acids are known to be key regulators of lipid, glucose and overall energy metabolism. Bile acid activation of the G protein-coupled receptor TGR5 has been shown to induce energy expenditure in muscle and brown fat, thereby conferring resistance to weight gain.

2 Sep 2009

Peptides News and Research

Stimulating effect of bioactive collagen peptides in cell experiments demonstrated

GENova to file for Prostaganin patents in the US and in Europe

Amylin and Biocon collaborate to develop a peptide therapeutic for treating diabetes

Merck update on the status of telcagepant clinical development programs

Phase II human clinical trial of Exsulin commences

Esperance Pharmaceuticals begins human clinical trials of its EP-100 cancer therapeutic candidate

UCSB researchers use lasers to deliver drugs into cancer cells

ARUP Laboratories' scientist receives grant to research HIV therapies

GENova Biotherapeutics files patent for Prostaganin anti-cancer drug

Iterative in situ click chemistry creates antibody-like protein-capture agents

Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth

CIHR funds for Alzheimer's and stroke research

New protein fragments identified for anthrax vaccine development

Researchers identify new molecular switch that produces cancer cells

Gloucester’s romidepsin recommended for approval by the FDA Oncologic Drug Advisory Committee

BioMS Medical update on dirucotide development

Hope for limiting skin toxicity of cancer drug users

Induced antibodies neutralize HIV-1; recognize peptides encapsulated in liposomes

Grant awarded to two researchers to study the role of GLP-1 in people at risk for or with diabetes

Paper discussing the mechanism of the selective TGR5 agonist INT-777 published in Cell Metabolism

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News